Global Plasma Protein Therapeutics Market Size By Type (Coagulation Factor, Immune Globulin), By Application (Application I, Application II), By Region, And Segment Forecasts, 2023 to 2032

The Global Plasma Protein Therapeutics Market was valued at USD 28.4 billion in 2023 and is projected to surpass USD 47.9 billion by 2031, expanding at a CAGR of 6.9% during the forecast period of 2023–2031. Growth is primarily driven by the increasing prevalence of rare and chronic diseases, rising global geriatric population, and expanding applications of plasma-derived therapies in immunology, neurology, and hematology. With innovations in plasma fractionation and improved collection infrastructure, the market is witnessing robust advancements in both developed and emerging regions.

Drivers:

1. Rising Incidence of Rare and Chronic Diseases:

Diseases such as primary immunodeficiency, hemophilia, and alpha-1 antitrypsin deficiency are major demand generators for plasma-derived therapies. Growing awareness and improved diagnostic rates are also driving consumption.

2. Aging Global Population:

The expanding geriatric demographic is more susceptible to chronic and immune-related conditions, necessitating long-term therapeutic plasma protein usage.

3. Technological Advancements in Plasma Collection & Processing:

New methods in plasma fractionation and improved donor screening are increasing supply and efficiency, contributing significantly to market growth.

Restraints:

1. High Cost and Complex Production:

Plasma protein therapeutics are expensive due to the intricate collection, processing, and regulatory requirements, limiting access in price-sensitive markets.

2. Supply Chain Dependence on Donor Plasma:

The market’s reliance on human plasma donors makes it vulnerable to disruptions, especially during pandemics or geopolitical instability.

Opportunity:

1. Expansion in Emerging Markets:

Countries in Asia-Pacific and Latin America are seeing improved healthcare infrastructure and awareness, providing fertile ground for market penetration.

2. Innovation in Recombinant Therapies:

Biopharmaceutical advancements in recombinant protein production offer scalable, consistent alternatives to plasma-derived therapies, opening up hybrid treatment avenues.

Market by System Type Insights:

The Immunoglobulin segment held the largest market share in 2023, attributed to its extensive use in treating immunodeficiency disorders and its rising off-label use in autoimmune diseases. The Albumin segment is projected to grow rapidly, fueled by increasing applications in liver disease and trauma care.

Market by End-use Insights:

Hospitals dominated the end-use segment in 2023, accounting for over 50% of the market share. Their dominance is attributed to the complexity of administration and monitoring required for plasma protein therapies. However, Homecare settings are expected to grow significantly due to the rising preference for self-administration, especially in developed economies.

Market by Regional Insights:

North America led the global market in 2023, owing to strong healthcare infrastructure, favorable reimbursement policies, and high awareness levels. Asia-Pacific is expected to register the fastest CAGR through 2031, supported by increasing investments in healthcare, rising disposable income, and government initiatives promoting rare disease diagnosis and treatment.

Competitive Scenario:

Major players in the market include CSL Behring, Grifols S.A., Takeda Pharmaceutical Company, Octapharma AG, Kedrion S.p.A., and Biotest AG. These companies are focusing on expanding their plasma collection networks, investing in R&D for next-gen therapies, and engaging in strategic collaborations. For example:

In 2024, Takeda expanded its global plasma collection footprint with new centers in Southeast Asia.

In 2023, Grifols introduced an advanced immunoglobulin formulation for improved tolerability.

In 2022, CSL Behring partnered with a biotech start-up for recombinant plasma protein development.

Scope of Work – Global Plasma Protein Therapeutics Market

Report Metric Details

Market Size (2023) USD 28.4 billion

Projected Market Size (2031) USD 47.9 billion

CAGR (2023–2031) 6.9%

Market Segments By System Type (Immunoglobulin, Albumin, Coagulation Factors), By End-use (Hospitals, Homecare)

Growth Drivers Rising prevalence of rare diseases, Aging population, Plasma collection innovation

Opportunities Expansion in emerging markets, Rise of recombinant protein therapies

Key Market Developments:

January 2024: CSL Behring announced regulatory approval for its long-acting albumin therapy in Europe.

August 2023: Grifols opened a new fractionation facility in North America to meet increasing global demand.

June 2022: Octapharma launched a digital platform for home delivery and virtual consultation of plasma therapies.

FAQs:

1) What is the current market size of the Global Plasma Protein Therapeutics Market?

The market was valued at USD 28.4 billion in 2023.

2) What is the major growth driver of the Global Plasma Protein Therapeutics Market?

The major driver is the rising prevalence of rare and chronic diseases requiring plasma-derived therapies.

3) Which is the largest region during the forecast period in the Global Plasma Protein Therapeutics Market?

North America holds the largest market share and is expected to maintain dominance.

4) Which segment accounted for the largest market share in Global Plasma Protein Therapeutics Market?

The Immunoglobulin segment held the largest market share in 2023.

5) Who are the key market players in the Global Plasma Protein Therapeutics Market?

Key players include CSL Behring, Grifols S.A., Takeda, Octapharma, and Kedrion.